Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention
Authors:
- Mary G. FowlerMFMary G. Fowler
- Min QinMQMin Qin
- Susan A. FiscusSFSusan A. Fiscus
- Judith S. CurrierJCJudith S. Currier
- Patricia M. FlynnPFPatricia M. Flynn
- Tsungai ChipatoTCTsungai Chipato
- James McIntyreJMJames McIntyre
- Devasena GnanashanmugamDGDevasena Gnanashanmugam
- George K. SiberryGSGeorge K. Siberry
- Anne S. ColettiACAnne S. Coletti
- Taha E. TahaTTTaha E. Taha
- Karin L. KlingmanKKKarin L. Klingman
Top Cited Papers
- 3 November 2016
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 375 (18) , 1726-1737
Abstract
Randomized-trial data on the risks and benefits of antiretroviral therapy (ART) as compared with zidovudine and single-dose nevirapine to prevent transmission of the human immunodeficiency virus (HIV) in HIV-infected pregnant women with high CD4 counts are lacking. We randomly assigned HIV-infected women at 14 or more weeks of gestation with CD4 counts of at least 350 cells per cubic millimeter to zidovudine and single-dose nevirapine plus a 1-to-2-week postpartum “tail” of tenofovir and emtricitabine (zidovudine alone); zidovudine, lamivudine, and lopinavir–ritonavir (zidovudine-based ART); or tenofovir, emtricitabine, and lopinavir–ritonavir (tenofovir-based ART). The primary outcomes were HIV transmission at 1 week of age in the infant and maternal and infant safety. The median CD4 count was 530 cells per cubic millimeter among 3490 primarily black African HIV-infected women enrolled at a median of 26 weeks of gestation (interquartile range, 21 to 30). The rate of transmission was significantly lower with ART than with zidovudine alone (0.5% in the combined ART groups vs. 1.8%; difference, −1.3 percentage points; repeated confidence interval, −2.1 to −0.4). However, the rate of maternal grade 2 to 4 adverse events was significantly higher with zidovudine-based ART than with zidovudine alone (21.1% vs. 17.3%, P=0.008), and the rate of grade 2 to 4 abnormal blood chemical values was higher with tenofovir-based ART than with zidovudine alone (2.9% vs. 0.8%, P=0.03). Adverse events did not differ significantly between the ART groups (P>0.99). A birth weight of less than 2500 g was more frequent with zidovudine-based ART than with zidovudine alone (23.0% vs. 12.0%, P<0.001) and was more frequent with tenofovir-based ART than with zidovudine alone (16.9% vs. 8.9%, P=0.004); preterm delivery before 37 weeks was more frequent with zidovudine-based ART than with zidovudine alone (20.5% vs. 13.1%, P<0.001). Tenofovir-based ART was associated with higher rates than zidovudine-based ART of very preterm delivery before 34 weeks (6.0% vs. 2.6%, P=0.04) and early infant death (4.4% vs. 0.6%, P=0.001), but there were no significant differences between tenofovir-based ART and zidovudine alone (P=0.10 and P=0.43). The rate of HIV-free survival was highest among infants whose mothers received zidovudine-based ART. Antenatal ART resulted in significantly lower rates of early HIV transmission than zidovudine alone but a higher risk of adverse maternal and neonatal outcomes. (Funded by the National Institutes of Health; PROMISE ClinicalTrials.gov numbers, NCT01061151 and NCT01253538.)Keywords
This publication has 23 references indexed in Scilit:
- Initiation of Antiretroviral Therapy in Early Asymptomatic HIV InfectionNew England Journal of Medicine, 2015
- Antiretroviral Therapy in Relation to Birth Outcomes among HIV-infected Women: A Cohort StudyThe Journal of Infectious Diseases, 2015
- Protease Inhibitors and Adverse Birth Outcomes: Is Progesterone the Missing Piece to the Puzzle?The Journal of Infectious Diseases, 2014
- HIV Protease Inhibitor Use During Pregnancy Is Associated With Decreased Progesterone Levels, Suggesting a Potential Mechanism Contributing to Fetal Growth RestrictionThe Journal of Infectious Diseases, 2014
- Mortality risk in preterm and small-for-gestational-age infants in low-income and middle-income countries: a pooled country analysisThe Lancet, 2013
- Highly Active Antiretroviral Therapy and Adverse Birth Outcomes Among HIV-Infected Women in BotswanaThe Journal of Infectious Diseases, 2012
- Child Mortality Levels and Trends by HIV Status in Blantyre, MalawiJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000The Lancet, 2012
- The Effect of Lopinavir/Ritonavir on the Renal Clearance of Tenofovir in HIV-infected PatientsClinical Pharmacology & Therapeutics, 2007
- Reduced lopinavir exposure during pregnancyAIDS, 2006